Understanding HMP: The Pathway Most Medical Students Glaze Over
HMP stands for Hexose Monophosphate, commonly referred to as the HMP shunt or pentose phosphate pathway. It is not a diagnostic test, a drug, or a disease marker. It is a metabolic route that runs parallel to glycolysis inside the cytoplasm, and its primary job is generating NADPH and ribose-5-phosphate, not ATP. That distinction matters more than people realize when they first encounter this term in a clinical context. I ran into this exact confusion last year while reviewing a lab request. A resident had ordered an "HMP screen" thinking it was some kind of standard blood panel. It was not. The correct order is a G6PD assay, possibly with a fluorescent spot test if the lab does not have enzymatic quantification available. The HMP pathway itself cannot be "screened" directly in routine clinical practice. What we actually measure are its downstream consequences: NADPH-dependent glutathione reduction in red blood cells, or the activity of glucose-6-phosphate dehydrogenase, the rate-limiting enzyme of the pathway. Here is how the pathway works in plain terms. Glucose-6-phosphate enters the oxidative phase and is converted to 6-phosphoglucono-delta-lactone by G6PD. That reaction reduces NADP+ to NADPH. The lactone is hydrolyzed to 6-phosphogluconate, which is then oxidatively decarboxylated by 6-phosphogluconate dehydrogenase, producing a second molecule of NADPH and ribulose-5-phosphate. The non-oxidative phase shuffles that five-carbon sugar into glycolytic intermediates via transketolase and transaldolase. The net yield per glucose-6-phosphate is two NADPH molecules and one ribose-5-phosphate, with no direct ATP production.
The reason this matters clinically is that NADPH is the reducing power that keeps glutathione in its active state inside red blood cells. Without it, hydrogen peroxide and other reactive oxygen species accumulate, hemoglobin denatures into Heinz bodies, and the RBC membrane gets damaged. That is hemolytic anemia, and in most real-world cases it traces back to G6PD deficiency, an X-linked condition affecting roughly 400 million people worldwide. The pathway itself is fine. The enzyme is not. A counter-intuitive point that rarely gets emphasized: a normal G6PD level between acute hemolytic episodes does not rule out deficiency. During an active hemolytic crisis, the oldest RBCs with the lowest enzyme activity are destroyed first, and the remaining population consists of younger reticulocytes that naturally have higher G6PD expression. I had a patient whose initial G6PD result came back at 12.4 U/g Hb, which looked normal on paper. He was still actively hemolyzing from a sulfa antibiotic trigger. We repeated the test eight weeks later after the reticulocyte count had normalized, and it dropped to 3.1 U/g Hb. The discrepancy saved us from a false-negative diagnosis. Another nuance people miss is that the HMP pathway is not uniformly active across all tissues. The liver, adrenal cortex, mammary gland, and red blood cells depend on it heavily for NADPH. Neurons and skeletal muscle rely on it minimally. When you see elevated riboflavin or niacin requirements in malnourished patients, part of that tracks back to these cofactors being necessary for HMP pathway enzymes to function properly. Thiamine deficiency impairs transketolase activity in the non-oxidative phase, which is why the erythrocyte transketolase activation test exists as a functional measure of vitamin B1 status. That is HMP-related diagnostics most clinicians never hear about.
The limitations are straightforward and worth stating plainly. There is no commercially available "HMP pathway activity" test. You cannot draw a tube and send it to a reference lab asking for HMP function. The pathway is inferred through enzyme assays, metabolite measurements, or clinical presentation. Genetic testing for G6PD mutations exists but is expensive and usually unnecessary unless you are dealing with atypical variants common in certain populations, such as the G6PD Mediterranean or G6PD Canton variants, which carry different severity profiles than the G6PD A- variant prevalent in African populations. If you are studying for boards, focus on the oxidative phase. That is where the clinically relevant chemistry lives. The non-oxidative phase is biochemically interesting but diagnostically quiet. Memorize that G6PD is the rate-limiting step, that NADPH protects against oxidative stress in RBCs, and that hemolysis triggers are drugs like primaquine, sulfonamides, dapsone, and nitrofurantoin, plus fava beans in the case of favism. That covers roughly 95 percent of what shows up on exams and probably 80 percent of what you will encounter in practice. The rest is footnotes.
Get the Full Details
